TICKERNERD
Menu
DSGNDSGNHealthcare · Biotechnology

DSGN Stock Forecast: Design Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$11
−1.71% on the day

The 8 Wall Street analysts covering Design Therapeutics, Inc. hold a median 12-month price target of $21 — +82.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$731.6M
Ticker Nerd rank
61 / 100
Median analyst target
$21
Analysts covering
8
Revenue$0.0
Operating income−$22.2M
Net income−$20.2M
Free cash flow−$15.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.1%
1M
−24.6%
YTD
+22.5%
1Y
+65.6%
From 52W high
−27.9%
From 52W low
+107.8%
$6
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DSGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Design Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
77
Accruals
72
Value
66
Revisions
60
Quality
54
Size
48
Volatility
43
Growth
41
Issuance
34

Momentum (77): The shares have been drifting up relative to others.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DSGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DSGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26DSGNHigh $26Median $21Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $20Median $21High $26

The green dot is the last close — the median target sits +82.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Oct 2026Wells FargoInitiatesOverweight$26
4 May 2026OppenheimerMaintainsOutperform—
4 May 2026OppenheimerMaintainsOutperform$18 → $21
16 Mar 2026JefferiesInitiatesBuy—
10 Mar 2026RBC CapitalMaintainsOutperform—
7 Jan 2026OppenheimerInitiatesOutperform—
3 Dec 2025Leerink PartnersUpgradeOutperform—
20 Nov 2025RBC CapitalUpgradeOutperform—
6 Nov 2025RBC CapitalMaintainsSector Perform—
6 Aug 2024RBC CapitalReiteratesSector Perform—
7 May 2024Piper SandlerUpgradeOverweight—
20 Mar 2024RBC CapitalReiteratesSector Perform—
20 Mar 2024WedbushReiteratesNeutral—
14 Nov 2023RBC CapitalMaintainsSector Perform—
15 Aug 2023RBC CapitalDowngradeSector Perform—
15 Aug 2023SVB LeerinkDowngradeMarket Perform—
15 Aug 2023WedbushDowngradeNeutral—
10 May 2023RBC CapitalMaintainsOutperform—
10 May 2023WedbushMaintainsOutperform—
4 May 2023Goldman SachsUpgradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DSGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DSGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Design Therapeutics, Inc. returned +65.6% against +16.2% for the S&P 500, dividends included.

DSGN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26DSGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DSGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

Design Therapeutics, Inc. (DSGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.6×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
3.6×

Cheaper than 27% of US stocks

EV / EBITDA
−6.7×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−34.1%

Higher than 26% of US stocks

Return on assets
−22.5%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Design Therapeutics, Inc. (DSGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Design Therapeutics, Inc. has a market value of $731.6M and an enterprise value of $526.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$70.8M.

  • Diluted earnings per share, trailing twelve months: $−1.18.

  • Free cash flow in the twelve months to 30 June 2026: −$55.1M.

  • Shares outstanding: 62.6M.

  • Trailing P/E: −9.6×; forward P/E: −7.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Design Therapeutics, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

DSGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DSGNDesign Therapeutics, Inc.$731.6M
61
CADLCandel Therapeutics, Inc.$707.6M
41
AVTXAvalo Therapeutics, Inc.$706.0M
36
VSTMVerastem, Inc.$712.3M
59
FDMT4D Molecular Therapeutics, Inc.$701.6M
56
SLDBSolid Biosciences, Inc.$717.0M
44
MDXGMiMedx Group, Inc.$686.4M
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Design Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DSGN news & analysis

Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027

Seeking Alpha · 4 Oct 2026neutral

Design Therapeutics was initiated with a "Hold" rating, with its lead candidate DT-216P2 targeting the root cause of Friedreich Ataxia. The 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements, but confirmation awaits 12-week results scheduled for Q1 2027, with a registrational update planned for Q4 2026.

Why it matters — A DSGN watcher would care because upcoming catalysts—the Q4 2026 registrational update for DT-216P2, Q1 2027 12-week results, and early-stage readouts for the DM1 and FECD programs—will indicate whether the promising early data translates into sustained clinical benefit for the company's pipeline.

Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, announced that its management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. in Carlsbad, California.

Why it matters — DSGN watchers may be interested in the company's participation in the conference as an opportunity to hear management discuss its programs and outlook in a fireside chat format.

Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch

24/7 Wall Street · 27 Aug 2026neutral

Design Therapeutics, a clinical-stage biotech with pivotal pipeline data, was placed on analysts' watch lists this week, according to 24/7 Wall Street. The item groups the company alongside an EV maker and a real-estate firm that analysts are covering for different reasons.

Why it matters — A DSGN watcher would care because the item highlights that analysts are turning attention to the company's pivotal pipeline data.

Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 3 Aug 2026positive

Design Therapeutics announced modifications to its RESTORE-FA clinical trial based on positive four-week data, expects 12-week dosing data in Q1 2027, initiated dosing in a Phase 1 trial of DT-818 for myotonic dystrophy type 1, and reported $207.4 million in cash and securities at the end of Q2 2026.

Why it matters — The update provides a clearer timeline for key data readouts from the RESTORE-FA trial and shows advancement of another pipeline candidate, DT-818, into clinical development.

FAQ

Frequently asked questions about DSGN stock

What is the DSGN stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Design Therapeutics, Inc. have a median 12-month price target of $21, with estimates ranging from $20 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DSGN stock a buy right now?

Of the 8 analysts covering Design Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Design Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DSGN?

As at 8 Oct 2026, Design Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).

Will DSGN stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +82.8% from the last close, and Ticker Nerd's factor model ranks Design Therapeutics, Inc. 61 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DSGN stock forecast for 2030?

No analyst covering Design Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DSGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $26 over the next 12 months.

How has DSGN stock performed over the past year?

Design Therapeutics, Inc. returned +65.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Design Therapeutics, Inc. do?

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases.

What is the latest news on DSGN?

The most recent item we track (Seeking Alpha, 4 Oct 2026): "Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027". Design Therapeutics was initiated with a "Hold" rating, with its lead candidate DT-216P2 targeting the root cause of Friedreich Ataxia. The 4-week phase 1/2 RESTORE-FA data showed strong biomarker and clinical improvements, but confirmation awaits 12-week results scheduled for Q1 2027, with a registrational update planned for Q4 2026.

Company

About Design Therapeutics, Inc.

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. Its approach centers on designing therapeutic candidates that act on the underlying genetic cause of disease rather than only addressing symptoms. Design Therapeutics serves the biotechnology and drug-development market through its proprietary platform, which supports research, preclinical work, and clinical development of novel medicines for patients with high unmet medical needs. The company is headquartered in Carlsbad, California.

CEO Mr. Pratik Shah Ph.D. · 55 employees · United States · https://www.designtx.com